Business Context and Reporting Period
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting Bitter Taste Receptors (TAS2Rs) to treat metabolic diseases, specifically hyperphagia associated with Prader-Willi Syndrome (PWS). This Form 10-K covers the fiscal year ended December 31, 2025. The company completed its Initial Public Offering (IPO) in February 2025.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(57.6) million | $(20.6) million |
| Research & Development Expenses | $48.9 million | $17.4 million |
| General & Administrative Expenses | $13.8 million | $5.3 million |
| Cash, Cash Equivalents & Short-Term Investments | $110.0 million | $73.7 million |
| Accumulated Deficit | $(115.9) million | $(58.3) million |
| Net Cash Used in Operating Activities | $(54.2) million | $(18.1) million |
Note: The company has no debt and no products approved for commercial sale.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $37.0 million year-over-year, driven primarily by a $31.6 million increase in R&D expenses and an $8.5 million increase in G&A expenses.
- R&D Expansion: R&D expenses more than doubled due to external costs for chemistry, manufacturing, controls (CMC), clinical, and toxicology studies related to the lead candidate ARD-101, as well as increased personnel costs.
- Liquidity Position: Cash and short-term investments increased to $110.0 million following the February 2025 IPO, which generated net proceeds of approximately $87.5 million.
- Stock Price Volatility: Following the announcement of a voluntary clinical trial pause in February 2026, the stock price declined significantly from $12.49 to $5.47 per share.
Guidance, Outlook, and Risks
Clinical Trial Pause (Critical Update)
On February 27, 2026, the company voluntarily paused enrollment and dosing in its Phase 3 HERO trial (ARD-101 for PWS) and the Open Label Extension (OLE) trial. This decision followed reversible cardiac observations (QRS duration increases) in a healthy volunteer study. The company is reviewing data with the FDA and expects to provide further guidance in the second quarter of 2026.
Impact on Pipeline
- ARD-101: The Phase 3 HERO trial is paused. The company no longer anticipates topline data in the third quarter of 2026.
- ARD-201: The Phase 2 POWER and STRENGTH trials (obesity indications) have also been voluntarily paused pending the evaluation of ARD-101 safety data.
Liquidity Outlook
Management believes existing cash resources ($110.0 million as of Dec 31, 2025) are sufficient to fund operations into the second quarter of 2027. However, the clinical trial pause may alter expenditure timing and future capital needs.
Key Risks
- Regulatory & Safety: Uncertainty regarding the resolution of cardiac safety signals and potential protocol changes required by the FDA.
- Capital Requirements: The company will require substantial additional financing to continue operations and development, which may result in dilution.
- Single Product Dependence: The business is heavily dependent on the successful development of ARD-101.
Investor Verification Checklist
- Clinical Trial Status: Verify the outcome of the FDA collaboration regarding the HERO trial pause and the timeline for resuming enrollment.
- Safety Data Review: Monitor the release of the comprehensive data review regarding the QRS duration observations in the healthy volunteer study.
- Cash Burn Rate: Assess the impact of the trial pause on the projected cash runway (currently estimated to Q2 2027) and the potential need for near-term capital raises.
- Protocol Amendments: Review any revised trial designs or dosing strategies proposed to the FDA to mitigate cardiac risks.
- Intellectual Property: Confirm the status of patent protection for ARD-101, noting key expiration dates (e.g., 2038, 2042) and orphan drug exclusivity.